Marinomed has already achieved many milestones in its short history. The selected scientific publications and press releases provide information on the most important events to date.
August 30, 2019
Marinomed: Investments in strong technology portfolio in first half-year 2019
May 29, 2019
Marinomed: Focus on future investments in Q1 2019
May 15, 2019
Marinomed Biotech AG: Budesolv with a strongly decreased dose of the active ingredient compared to the marketed product Rhinocort Aqua shows pronounced efficacy already after first application – clinical validation of the Marinosolv® platform
April 30, 2019
In 2018, Marinomed set the course for accelerated growth
April 23, 2019
Marinomed Biotech AG announces top line results of the Phase III study for Budesolv
February 28, 2019
Marinomed Biotech AG: Greenshoe option fully exercised
February 26, 2019
Marinomed receives EUR 15m EIB financing
February 18, 2019
Marinomed announces result of conversion of convertible bonds
January 29, 2019
Marinomed sets offer price at 75 Euro per share
January 29, 2019
Marinomed announces strong investor demand and expected offer price
January 23, 2019
Marinomed resumes offer period of the IPO
December 21, 2018
Screening of pivotal clinical trial completed
November 29, 2018
Marinomed suspends offer period of the current IPO
November 28, 2018
Viennese biotech company Marinomed demonstrates the benefits of its patented Marinosolv® technology
November 16, 2018
Marinomed determines IPO timeline and terms
November 05, 2018
Marinomed intends to conduct an IPO on the Vienna Stock Exchange
October 19, 2018
Initiation of Phase III clinical trial
August 29, 2018
Vienna-based biotech company Marinomed on a growth path
August 07, 2018
Vienna-based Biotech Company Marinomed obtains EU-wide Certification for new cold Medication
July 31, 2018
Pascal Schmidt appointed CFO as Vienna based biotech firm Marinomed strengthens its management team – Company reports strong growth.
November 27, 2017